0.324
price up icon2.21%   0.007
pre-market  시장 영업 전:  .33   0.006   +1.85%
loading
전일 마감가:
$0.317
열려 있는:
$0.3165
하루 거래량:
3.78M
Relative Volume:
0.15
시가총액:
$16.52M
수익:
-
순이익/손실:
$-12.89M
주가수익비율:
-0.1281
EPS:
-2.53
순현금흐름:
$-11.95M
1주 성능:
-8.16%
1개월 성능:
+4.89%
6개월 성능:
-72.78%
1년 성능:
-82.86%
1일 변동 폭
Value
$0.3165
$0.339
1주일 범위
Value
$0.3165
$0.365
52주 변동 폭
Value
$0.1634
$2.3099

Plus Therapeutics Inc Stock (PSTV) Company Profile

Name
명칭
Plus Therapeutics Inc
Name
전화
737.255.7194
Name
주소
4200 MARATHON BLVD., AUSTIN, TX
Name
직원
21
Name
트위터
@plustxinc
Name
다음 수익 날짜
2024-11-04
Name
최신 SEC 제출 서류
Name
PSTV's Discussions on Twitter

PSTV을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PSTV
Plus Therapeutics Inc
0.324 17.99M 0 -12.89M -11.95M -2.53
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.55 123.00B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.93 59.66B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
322.81 41.84B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
577.92 33.98B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
279.16 27.67B 3.81B -644.79M -669.77M -6.24

Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-17 개시 D. Boral Capital Buy
2021-01-25 개시 Ladenburg Thalmann Buy
2020-10-16 개시 Maxim Group Buy

Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스

pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Announces Clinical Trial Presentation and Educational Symposium at 2025 SNO/ASCO CNS Metastases Conference - Nasdaq

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial - GlobeNewswire

Jul 15, 2025
pulisher
Jul 15, 2025

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - Yahoo Finance

Jul 15, 2025
pulisher
Jul 11, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewswire

Jul 11, 2025
pulisher
Jul 10, 2025

Plus Therapeutics Announces Two CNSide Presentations at the Upco - GuruFocus

Jul 10, 2025
pulisher
Jul 10, 2025

Plus Therapeutics' CNSide Showcases Innovative CSF Assay Data at SNO/ASCO CNS Metastases Conference 2025 - Nasdaq

Jul 10, 2025
pulisher
Jul 10, 2025

Revolutionary CNS Cancer Detection: Plus Therapeutics Unveils Game-Changing Clinical Data at Major Conference - Stock Titan

Jul 10, 2025
pulisher
Jul 09, 2025

Plus Therapeutics Soars 10.51% on Promising Clinical Trial Results - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully - GlobeNewswire

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics begins treatment in REYOBIQ dose optimization trial - Investing.com

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases | PSTV Stock News - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics announces initial patients successfully treated in ReSPECT-LM dose optimization trial for Reyobiq™ in leptomeningeal metastases - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Initiates ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases Treatment - Nasdaq

Jul 08, 2025
pulisher
Jul 08, 2025

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Breakthrough Brain Cancer Drug REYOBIQ Achieves 80% Tumor Reduction in Phase 1 Trial, Advances to Next Stage - Stock Titan

Jul 08, 2025
pulisher
Jul 01, 2025

Stock under $1with a very strong catalyst to buy and hold for a minimum of three years - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - The Manila Times

Jun 30, 2025
pulisher
Jun 29, 2025

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM - GuruFocus

Jun 29, 2025
pulisher
Jun 27, 2025

Plus Therapeutics stock price target lowered to $3 at H.C. Wainwright - Investing.com India

Jun 27, 2025
pulisher
Jun 26, 2025

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary | PSTV Stock News - GuruFocus

Jun 26, 2025
pulisher
Jun 25, 2025

Plus Therapeutics (PSTV) Shares Surge After FDA Trial Clearance - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Plus Therapeutics Soars 122.46% on FDA Clearance for Pediatric Brain Cancer Trial - AInvest

Jun 25, 2025
pulisher
Jun 24, 2025

Plus Therapeutics (PSTV) Restructures $15M Equity Financing to Minimize Dilution | PSTV Stock News - GuruFocus

Jun 24, 2025
pulisher
Jun 20, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering - MSN

Jun 20, 2025
pulisher
Jun 19, 2025

Plus (PSTV) Upgraded to Buy: Here's Why - Yahoo Finance

Jun 19, 2025
pulisher
Jun 18, 2025

Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha

Jun 18, 2025
pulisher
Jun 18, 2025

Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Crude Oil Moves Higher; US Weekly Jobless Claims Decline - Benzinga

Jun 18, 2025
pulisher
Jun 17, 2025

Plus Therapeutics Modifies Security Holders’ Rights - TipRanks

Jun 17, 2025
pulisher
Jun 10, 2025

Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com

Jun 10, 2025
pulisher
Jun 09, 2025

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet

Jun 09, 2025
pulisher
Jun 06, 2025

Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks

Jun 06, 2025
pulisher
Jun 06, 2025

Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com

Jun 05, 2025
pulisher
Jun 05, 2025

Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa

Jun 05, 2025
pulisher
Jun 05, 2025

Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com

Jun 05, 2025
pulisher
Jun 05, 2025

PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened - Defense World

Jun 05, 2025
pulisher
Jun 03, 2025

Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks

Jun 03, 2025
pulisher
Jun 03, 2025

Plus Therapeutics Plunges 14.13% on Q1 Earnings Miss - AInvest

Jun 03, 2025
pulisher
Jun 02, 2025

Why Did Plus Therapeutics (PSTV) Soar 36.24% Pre-Market After Earnings Miss? - AInvest

Jun 02, 2025
pulisher
Jun 02, 2025

Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus

Jun 02, 2025
pulisher
Jun 01, 2025

Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN

Jun 01, 2025
pulisher
May 31, 2025

Plus: Q1 Earnings Snapshot - New Haven Register

May 31, 2025
pulisher
May 30, 2025

Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks

May 30, 2025
pulisher
May 30, 2025

Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus

May 30, 2025

Plus Therapeutics Inc (PSTV) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.87
price up icon 3.40%
$35.60
price down icon 2.49%
$104.59
price up icon 1.67%
$28.27
price up icon 16.05%
$112.49
price up icon 1.66%
biotechnology ONC
$279.16
price up icon 3.51%
자본화:     |  볼륨(24시간):